makinezmoney
1年前
$NRXS: Fiyyyaaaaahhhhhhhhhhhh..... now $6.20 in PM
Mannnnnnnnnnn whatta booster........... opened at $2.40 today.
Look at it go here.
GO $NRXS
********************************************************************
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pediatric FAP/Functional Dyspepsia (FD) and Associated Nausea Symptoms NRXS
- Significantly expands IB-Stim's total addressable market -- Clearance covers patients aged 8--21 -- Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis, " or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for IB-Stim(TM) for the treatment of Pediatric Functional Abdominal Pain (FAP) associated with Functional Dyspepsia, and FD related Nausea Symptoms, in patients aged 8 to 21 years. This clearance is the second successful expanded FDA indication for IB-Stim, following its initial approval for Functional Abdominal Pain associated with Irritable Bowel Syndrome (IBS). The new indication represents the first treatment ever cleared or approved by the FDA related to functional dyspepsia. It is expected to nearly double the Company's total addressable market, reinforcing NeurAxis' leadership in non-invasive, pediatric-focused neuromodulation. The indication leverages the same CPT code, insurance coverage, and provider call points as the existing IBS indication, supporting a seamless and capital-efficient go-to-market strategy. Commercial rollout for this expanded important indication will begin immediately. "This latest FDA clearance represents a pivotal milestone in NeurAxis' growth strategy," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "Expanding into the treatment of Pediatric Functional Dyspepsia pain that includes related nausea symptoms, not only broadens our clinical impact but also positions us to drive significant revenue growth through a capital-efficient rollout. This progress is fueled by a robust body of clinical evidence supporting our PENFS technology, which continues to gain traction among providers and payers. Notably, we are seeing expanded insurance coverage and, most recently, the American Medical Association's approval of a new CPT Category I code for IB-Stim, which will take effect in January 2026." "Functional dyspepsia can cause severe abdominal pain and nausea, and in adolescents, it often leads to serious secondary issues like fear of eating, weight loss, and significant dietary restriction," said Dr. Adrian Miranda, Chief Medical Officer of NeurAxis. "We are thrilled by the agency's decision, which gives us the opportunity to offer real hope to thousands of patients and their families who have had limited options--until now." NeurAxis' PENFS technology, IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia in adolescents 8-21 years old. IB-Stim is a non-surgical device that sends gentle electrical impulses into cranial nerve bundles in the ear. There are currently no FDA-approved drug therapies for children with abdominal pain-related disorders of the gut-brain interaction (DGBI's). Pharmacologic treatments that use drugs off-label can often have serious side effects, and most lack scientific evidence of efficacy. About NeurAxis, Inc. NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim(TM) therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim(TM) is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com. Forward-Looking Statements Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company's stock, public health issues or other events, the Company's compliance with applicable laws, the results of the Company's clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis's public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. For Contraindications, Precautions, Warnings, and IFU, please see: https://ibstim.com/important-information/ Contacts: Company NeurAxis, Inc. info @scart-9701 shamsian@lythampartners.com (END) Dow Jones Newswires May 20, 2025 08:00 ET (12:00 GMT) Story ID: 20250520SN006537 Keywords: DOW JONES CONTENT SET SN, SIGNIFICANT STORY, HEALTH CARE, GRAND CENTRAL ASSET CLASS EQUITIES, PRESS RELEASE WIRES, GLOBENEWSWIRE, COMPANY NEWS, NEW PRODUCTS & SERVICES, MEDICAL EQUIPMENT Symbols: NRXS
TacoTuesdayz
3年前
Aug. 22, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS), (“NeurAxis,” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two recently published independent studies showing that IB-Stim therapy leads to improvements in abdominal pain and disability in adolescents with IBS and that the gut microbiome may play an important role.
The publications, “The microbiome in adolescents with irritable bowel syndrome and changes with percutaneous electrical nerve field stimulation1,” authored by Daniel F. Castillo, et al, and “Impact of auricular percutaneous electrical nerve field stimulation on gut microbiome in adolescents with irritable bowel syndrome: a pilot study2,” authored by Geetanjalo Bora, et al, both highlight the effect of the gut microbiome in the treatment of adolescents with IBS using IB-Stim, NeurAxis’s proprietary technology.
Golden Cross
3年前
$NRXS NeurAxis Announces Over $8 Million in IB-Stim™ Revenue
https://ir.neuraxis.com/news-releases/news-release-details/neuraxis-announces-over-8-million-ib-stimtm-revenue
08/17/23
CARMEL, Ind., Aug. 17, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has generated over $8 million in revenue following the commercial launch of its proprietary IB-Stim™ technology. Sales began after NeurAxis received FDA clearance for IB-Stim™ in the pediatric treatment of functional abdominal pain and irritable bowel syndrome. NeurAxis is conducting clinical trials with IB-Stim™ for four additional pediatric indications, including chronic nausea, post-concussion syndrome, chemotherapy induced nausea and vomiting, and cyclic vomiting syndrome.
Approximately $2 million of the over $8 million in IB-Stim™ revenue through March 31, 2023 was generated in 2020 and 2019.
Brian Carrico, Chief Executive Officer of NeurAxis, said, “We are pleased to have reached over $8 million in sales of our proprietary IB-Stim™ technology and look forward building upon our momentum with the funds received from our recently completed IPO. We continue to drive increasing adoption of our IB-Stim™ therapy, supported by a significant and growing body of positive clinical data and commercial large health insurance company payor support. We believe the growing movement of patients gravitating towards non drug related therapies, especially for children, will continue to fuel our rapidly increasing adoption and the market for our new indications.”
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
The estimated revenues generated in 2019 and 2020 reflect our estimated financial results which were not audited nor reviewed by an independent registered public accounting firm.
Contacts:
Company
NeurAxis, Inc.
info @neuraxis.com
Investor Relations
Gilmartin Group
IR@neuraxis.com
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
QuicKtip
3年前
SidewaysTrader
3年前
SpaceManTrades
3年前
メールアドレスで登録
